A copy of the ESMO poster can be found on the Publications page of Checkpoint's website. In November 2024, Checkpoint received $9.2 million in cash proceeds through the exercise of existing warrants.

EMA granted clearance to advance belrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in the EU- Interim data from inupadenant Phase 2 A2A-005 in ...

Details on the ESMO posters are below. Posters will be available on the 23andMe Therapeutics and Investor websites following the presentations. About 23ME-0061023ME-00610 is a first-in-class anti ...

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 4, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global ...

Also, the slides from the oral presentation given at the Society for Melanoma Research in September is available on our website and the upcoming poster, which will be presented ... we presented an ...

Announced encouraging initial Phase 2 data of BDTX-1535 in patients with recurrent EGFRm NSCLC with a broad spectrum of classical, non-classical, ...

The SITC posters will be available on ImCheck's corporate website after the poster sessions have been opened.

The presentation will expand on safety, tolerability and immunogenicity results of the CVGBM trial presented last month at the European Society for Medical Oncology (ESMO) Congress, which demonstrated ...

Q3 2024 Earnings Call Transcript November 7, 2024 4:30 AM ETCompany ParticipantsBruce Mackle - LifeSci Advisors, ...

First patient dosed in Phase 1 clinical trial evaluating ZW171 in advanced mesothelin (MSLN)-expressing cancers Preclinical data presented on ...

This approval marks the second international marketing authorization for sugemalimab outside of China, following its ...

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary b ...